Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC Form 6-K October 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc

(the

Company

Transaction notification

Details of PDMR/person closely associated with 1. them ('PCA')

a) Name Ms C Thomas b) Position/status SVP, HR

Initial notification/

Initial notification c) amendment

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or

auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated

for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description

Ordinary shares of 25 pence of each ('Ordinary Shares') the ISIN: GB0009252882

financial

a)

instrument

Acquisition of Ordinary

Shares following the

Nature re-investment of dividends of b) paid to shareholders on 13 the October 2016 on shares held transaction

in the Deferred Annual

Bonus Plan Post-Tax.

Price(s) Volume(s) Price(s) £17.0319 32.163 and volume(s)

£17.0319 32.345

n/a (single transaction)

Aggregated information

d) Aggregated volume Price

Date of

e) the 2016-10-13

transaction

f) Place London Stock Exchange

of (XLON)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

the transaction

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: October 17, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc